Landos Biopharma, Inc.
LABPNASDAQHealthcare
$22.93
+$0.13(+0.57%)
Market Cap$71675511
P/E Ratio—
52W High$22.94
52W Low$3.145
Landos Biopharma, Inc.（LABP）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · LABP · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $0.04B | $0.04B | $0.09B | $0.03B | $0.05B |
| Net Receivables | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Inventory | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Current Assets | $0.04B | $0.05B | $0.09B | $0.03B | $0.05B |
| PP&E Net | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Goodwill | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Intangible Assets | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Assets | $0.04B | $0.05B | $0.09B | $0.03B | $0.05B |
| Liabilities | |||||
| Short-Term Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Accounts Payable | $0.00B | $0.00B | $0.01B | $0.01B | $0.00B |
| Total Current Liabilities | $0.01B | $0.01B | $0.02B | $0.01B | $0.00B |
| Long-Term Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Liabilities | $0.01B | $0.01B | $0.02B | $0.08B | $0.08B |
| Stockholders Equity | |||||
| Retained Earnings | ($0.16B) | ($0.13B) | ($0.09B) | ($0.06B) | ($0.03B) |
| Total Stockholders Equity | $0.03B | $0.04B | $0.08B | ($0.05B) | ($0.03B) |
| Total Liab & Equity(computed) | $0.04B | $0.05B | $0.09B | $0.03B | $0.05B |
| Debt Summary | |||||
| Total Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Debt | ($0.04B) | ($0.04B) | ($0.01B) | ($0.00B) | ($0.01B) |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Landos Biopharma, Inc.
关于Landos Biopharma, Inc.（LABP）资产负债表
Landos Biopharma, Inc.总资产$0.04B，现金及短期投资$0.04B，总负债$0.01B，总债务$0.00B，股东权益$0.03B。
常见问题
LABP · 4 问Landos Biopharma, Inc.总债务$0.00B，净债务($0.04B)。
LABP total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10